Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
NCT ID: NCT06451861
Last Updated: 2025-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
240 participants
INTERVENTIONAL
2024-08-21
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
NCT06928376
Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML
NCT05654194
Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML
NCT05053425
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
NCT06386302
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
NCT04801797
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ABC-14 regimen
AZA,Venetoclax,Chidamide
Chidamide
Induction Therapy
Venetoclax
Induction Therapy
azacitidine
Induction Therapy
3+7 chemotherapy regimen
Daunorubicin/idarubicin/mitoxantrone and cytarabine
Anthracyclines or anthraquinones
Induction Therapy
cytarabine
Induction Therapy
AB-14 regimen
AZA,Venetoclax
Venetoclax
Induction Therapy
azacitidine
Induction Therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chidamide
Induction Therapy
Venetoclax
Induction Therapy
azacitidine
Induction Therapy
Anthracyclines or anthraquinones
Induction Therapy
cytarabine
Induction Therapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥18 years old;
3. ECOG≤4;
4. The fertile woman agrees to use effective contraception during the treatment period and up to 3 months after the end of the treatment; Sign the informed consent form.
Exclusion Criteria
2. Resistance to azacytidine, azacitidine, Venetoclax;
3. Inability to take oral medication;
4. Combined with uncontrolled active infections (including bacterial, fungal or viral infections);
5. Combined with uncontrolled major organ dysfunction: cardiac insufficiency, decompensated liver insufficiency, moderate/severe renal insufficiency, etc.;
6. Participating in other clinical studies that affect the main purpose of this study; Patients deemed unsuitable for participation in this study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Provincial People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jianyu Weng
Role: PRINCIPAL_INVESTIGATOR
Guangdong Provincial People Hosptial
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dongguan General Hosptial
Dongguan, Guangdong, China
Foshan First People's Hospital
Foshan, Guangdong, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
The Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Shenzhen second people's Hospital
Shenzhen, Guangdong, China
Affiliated Hospital of Guangdong Medical University
Zhanjiang, Guangdong, China
Zhuhai General Hosptial
Zhuhai, Guangdong, China
Hainan General Hosptial
Haikou, Hainan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
yirong Jiang
Role: primary
Ying Zhao
Role: primary
Xin Du
Role: primary
Jianyu WENG
Role: backup
yang Liang
Role: primary
Runhui Zheng
Role: primary
xueyi Pan
Role: primary
Zhenqian Huang
Role: primary
Liye Zhong
Role: primary
xu Ye
Role: primary
xin Du
Role: primary
Yuming ZHANG
Role: primary
xiaoliang Li
Role: primary
Li'e Lin
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ABC-14_101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.